ArticlePediatric nephrology (Berlin, Germany)2026
Continuous kidney replacement therapy with CARPEDIEM
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world modality selection and outcomes in neonatal kidney replacement therapy: a single-center cohort study.European journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) affects 30% of hospitalized pediatric patients, with high mortality in neonates. The Cardio-Renal Pediatric Dialysis Emergency Machine
methodsWe retrospectively evaluated the technical feasibility, efficacy regarding solute and fluid removal, tolerability and patient outcomes of CKRT with CARPEDIEM
resultsTen neonates with a median gestational age of 31 [interquartile 29-32] (range 25-38) weeks and a birth weight of 1.1 [IQ 1.0-1.7] (0.6-2.0) kilograms received continuous veno-venous hemofiltration (CVVH) during 22 sessions. CVVH was initiated at a median age of 6 [2-12] (1-72) days and a weight of 1.9 [1.5-2.4] (1.3-2.8) kg. All CVVH sessions achieved efficient blood purification. At CVVH initiation fluid overload was 29 [21-39] (11-68)% and improved until the end of treatment to 16[8-18] (0-40)% (p = 0.04). Thrombocytopenia, requiring platelet transfusion, and hypotensive episodes were the main complications observed in 14 and 13 sessions. No deaths occurred during the CARPEDIEM
conclusionCVVH using CARPEDIEM
Indexed as
Identifiers
40668378What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.